Login
Make A Payment
< Back To PhiaGroup Home Page
Members Area
FAQs
FAQ - Subrogation & Reimbursement
FAQ - Mass Tort Subrogation & Reimbursement
Questionnaire Response
X
< Back To PhiaGroup Home Page
Members Area
FAQs
FAQ - Subrogation & Reimbursement
FAQ - Mass Tort Subrogation & Reimbursement
Questionnaire Response
< Back To PhiaGroup Home Page
+
Members Area
+
FAQs
FAQ - Subrogation & Reimbursement
FAQ - Mass Tort Subrogation & Reimbursement
Questionnaire Response
Industry Articles
Top Five Advantages of RBP Plans
Guide to Understanding Subrogation
Moving To Self-Funded Health Plan Guide
Reference-Based Pricing Explained
Hospital Price Transparency Guide
Balance-Billing: What Patients Need To Know
Employee Rights With COVID-19 Vaccines
The No Surprises Act Explained
Mental Health Parity and Addiction Equity Act Explained
Understanding Non-Quantitative Treatment Limitations (NQTLs)
The Insulin Cap Bill Offers Hope for Americans With Diabetes
In-Network vs Out-of-Network Claims
Gag Clause Prohibition Compliance Attestation
AI in Healthcare
Understanding Prescription Medication for Weight Loss
Webinars
Newsletters
Blog
Podcasts
Press Releases
Industry Terms
Publications
Phia Group
Phia Group Media
Empowering Plans: P188 – Fiduciary Duties in the Spotlight – Lewandowski v. Johnson and Johnson
On April 25, 2024
Attorneys Brady Bizarro and Andrew Silverio discuss the pending case of Lewandowski v. Johnson & Johnson, a lawsuit brought against plan fiduciaries for violating their fiduciary duties under ERISA. How did they violate those duties? By failing to negotiate drug prices and sufficiently oversee their PBM or investigate alternatives. No matter who wins, this case highlights the importance of ERISA’s fiduciary duties and the gravity of the decisions fiduciaries are (or should be) making.
film izle